Preclinical
The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
amcure, a biopharmaceutical company developing first-in-class cancer therapeutics, will present a poster on the mode of action of its lead candidate AMC303 at the upcoming American Association for Cancer Research Annual Meeting.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
The polar vortex that brought bone-chilling temperatures to much of the United States earlier this winter highlighted a near constant concern – an inadequate supply of platelets at blood centers across the country.
Grace and Blanche, who were second cousins, for a time were believed to be the oldest living mice in the world prior to their death.
The artificial womb technology was able to maintain extremely preterm lamb fetuses, which were equivalent to a human fetus at 24 weeks of gestation.
The two companies will work on a preclinical target in hopes of finding new therapies for autoimmune diseases that regulate immune cell metabolism.
The study will focus on whether or not treatment with progesterone will counter-act the first dose of a chemical-induced abortion medication.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
PRESS RELEASES